Profile
| Metric | Value |
|---|---|
| Full Name | Centessa Pharmaceuticals plc |
| Ticker | NASDAQ: CNTA |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United Kingdom |
| IPO | |
| Indexes | Not included |
| Website | centessa.com |
| Employees | 86 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $22.69 | |
| Price, 1D Change | +0.04% | |
| Market Cap | $3B | |
| - | ||
| PE Ratio | - | |
| Beta | 0.99 | |
| Revenue | $0 | |
| Revenue, 1Y Change | -100.00% | |
| EPS | -$2.06 | |
| EPS, 1Y Change | -30.65% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | N/A | |
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$2.06 | |
| EPS Estimate | -$1.34 | |
| EPS Est. Change | +34.82% | |
| Revenue | $0.00 | |
| Revenue Estimate | $15.71M | |
| Revenue Est. Change | - | |
| Current Price | $22.69 | |
| Price Target | - | $36.00 |
| Price Tgt. Change | - | +58.66% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$1.67 | -$1.58 | +5.57% | |
| -$1.43 | -$2.06 | -44.08% | |
| -$1.34 | N/A | +34.82% | |
| -$1.65 | N/A | +20.11% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| - | $6.88M | - | |
| - | $0.00 | - | |
| $15.71M | N/A | - | |
| $1.90M | N/A | - |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +31.00% | |
| Price, 3Y | +579.34% | |
| Market Cap, 1Y | +46.01% | |
| Market Cap, 3Y | +958.80% | |
| Revenue, 1Y | -100.00% | |
| Revenue, 3Y | 0.00% | |
| EPS, 1Y | -30.65% | |
| EPS, 3Y | +51.44% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $22.69 | |
| SMA 200 | $18.63 | |
| SMA 200 vs Price | -17.88% | |
| SMA 50 | $26.00 | |
| SMA 50 vs Price | +14.61% | |
| Beta | 0.99 | |
| ATR | $1.22 | |
| 14-Day RSI | 30.12 | |
| 10-Day Volatility | 32.04% | |
| 1-Year Volatility | 61.15% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $0.00 | |
| EPS | -$2.06 | |
| Gross Profit | -$942.40K | |
| Gross Margin | - | |
| Operating Profit | -$201.14M | |
| Operating Margin | - | |
| Net Income | -$235.86M | |
| Net Margin | - | |
| EBITDA | -$200.20M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.29 | |
| Current Ratio | 9.25 | |
| Quick Ratio | 9.25 | |
| Interest Coverage | - | |
| - | ||
| Altman Z-Score | 8.77 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 222.75 | |
| PB Ratio | 11.12 | |
| EV/EBITDA | -15.17 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $401.54M | |
| Cash & Equivalents | $482.18M | |
| Total Assets | $579.50M | |
| Current Assets | $536.41M | |
| Total Liabilities | $177.95M | |
| Current Liabilities | $58.00M | |
| Total Debt | $117.23M | |
| Short Term Debt | $0.00 | |
| Accounts Payable | $7.14M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $235.86M | |
| Operating Expenses | $200.20M | |
| Cost Of Goods Sold | $942.40K | |
| SG&A | $50.83M | |
| D&A | $942.40K | |
| Interest Expense | $0.00 | |
| Income Tax | $2.85M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$142.11M | |
| CFI | $31.28M | |
| CFF | $364.91M | |
| Capex | $34.00K | |
| Free Cash Flow | -$142.15M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Chardan Capital | → | |
| Oppenheimer | → | |
| B. Riley Securities | → | |
| Guggenheim | → | |
| Wells Fargo | → | |
| Wells Fargo | → | |
| Stephens & Co. | ||
| Guggenheim | → | |
| Wells Fargo | ||
| Chardan Capital | → |
Analyst sentiment
Institutional ownership
Screeners with CNTA
Data Sources & References
- CNTA Official Website centessa.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1847903/000184790325000156/0001847903-25-000156-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1847903/000184790325000051/0001847903-25-000051-index.htm
- CNTA Profile on Yahoo Finance finance.yahoo.com/quote/CNTA
- CNTA Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/cnta
FAQ
What is the ticker symbol for Centessa Pharmaceuticals plc?
The ticker symbol for Centessa Pharmaceuticals plc is NASDAQ:CNTA
Does Centessa Pharmaceuticals plc pay dividends?
No, Centessa Pharmaceuticals plc does not pay dividends
What sector is Centessa Pharmaceuticals plc in?
Centessa Pharmaceuticals plc is in the Healthcare sector
What industry is Centessa Pharmaceuticals plc in?
Centessa Pharmaceuticals plc is in the Biotechnology industry
What country is Centessa Pharmaceuticals plc based in?
Centessa Pharmaceuticals plc is headquartered in United Kingdom
When did Centessa Pharmaceuticals plc go public?
Centessa Pharmaceuticals plc initial public offering (IPO) was on May 28, 2021
Is Centessa Pharmaceuticals plc in the S&P 500?
No, Centessa Pharmaceuticals plc is not included in the S&P 500 index
Is Centessa Pharmaceuticals plc in the NASDAQ 100?
No, Centessa Pharmaceuticals plc is not included in the NASDAQ 100 index
Is Centessa Pharmaceuticals plc in the Dow Jones?
No, Centessa Pharmaceuticals plc is not included in the Dow Jones index
When was Centessa Pharmaceuticals plc last earnings report?
Centessa Pharmaceuticals plc's most recent earnings report was on November 5, 2025
When does Centessa Pharmaceuticals plc report earnings?
The next expected earnings date for Centessa Pharmaceuticals plc is March 24, 2026